Gilead sees positive data in Phase III CF trial

Gilead Sciences released upbeat data from its late-stage study of inhaled antibiotic aztreonam lysine for cystic fibrosis. Researchers said that CF volunteers in the study with pulmonary Pseudomonas aeruginosa improved the amount of time needed for antibiotics. Patients also demonstrated an improvement in pulmonary function and respiratory symptoms.

"Pulmonary pseudomonal infection remains the leading cause of sickness and death in people with CF," said researcher Karen McCoy, chief of the division of pediatric pulmonology and associate professor of pediatrics at Ohio State University College of Medicine. "Data from the AIR-CF2 study indicate that aztreonam lysine for inhalation may provide broad clinical benefit, which is particularly significant given that most patients in the study had relatively long-standing CF, a history of frequent antibiotic use and impairment of lung function at the start of the study."

- see this summary of the data
- read the UPI report

ALSO: Gilead saw a 55 percent increase in first quarter earnings based on the strong performance of its HIV therapies. Release